Scholarlink

Purpose <p>Breast cancer incidence in Asian women peaks in the mid-40&#xa0;s, when many remain premenopausal. The progression of chemotherapy-induced menopausal symptoms in this population remains underexplored. This study examined their temporal trajectory and clinical significance during adjuvant chemotherapy.</p> Method <p>This prospective study assessed breast cancer patients undergoing adjuvant chemotherapy at a tertiary hospital. Participants were classified by menopausal status and treated with AC-D (Adriamycin, Cyclophosphamide, and Docetaxel) or FAC (5-Fluorouracil, Adriamycin, and Cyclophosphamide) regimens. Menopausal symptoms were evaluated using the Menopausal Rating Scale (MRS) at four time points: before chemotherapy (T0), after the first (T1) and fourth (T2) cycles, and one month post-chemotherapy (T3). Symptom trajectories were analyzed using a linear mixed-effects model (LMM) and Generalized Estimating Equations (GEE).</p> Results <p>Menopausal symptoms significantly worsened in premenopausal women (AC-D: <i>p</i> &lt; 0.001, FAC: <i>p</i> &lt; 0.001), particularly from T2 onward. Psychological symptoms showed the greatest increase (AC-D: <i>p</i> &lt; 0.001, FAC: <i>p</i> &lt; 0.001), followed by significant worsening of urogenital symptoms (AC-D: <i>p</i> = 0.002, FAC: <i>p</i> = 0.004). Somatic symptoms showed a non-significant increasing trend (AC-D: <i>p</i> = 0.120, FAC: <i>p</i> = 0.101). At T3, 67.9% of AC-D and 59.4% of FAC patients experienced moderate-to-severe symptoms, with severe cases doubling in AC-D (from 16.1% at T0 to 37.5%) and tripling in FAC (6.8% at T0 to 18.9%).</p> Conclusion <p>Chemotherapy-induced menopausal symptoms progressively worsened, particularly psychological symptoms. By treatment completion, approximately two-thirds required clinical intervention, underscoring the need for early assessment and proactive management to improve patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Longitudinal trajectory of menopausal symptoms in premenopausal women throughout adjuvant chemotherapy: a two-stage analytical approach

  • 期刊论文

  • 发表日期：

    2025年10月14日

查看全文
  • Saim Jung,
  • Jaehyun Kim,
  • Sun Hyung Lee,
  • Joon Sung Shin,
  • Won-Hyoung Kim,
  • Dooyoung Jung,
  • Tae-Yong Kim,
  • Seock-Ah Im,
  • Kyung-Hun Lee,
  • Bong-Jin Hahm,
  • Chan-Woo Yeom

摘要

Purpose

Breast cancer incidence in Asian women peaks in the mid-40 s, when many remain premenopausal. The progression of chemotherapy-induced menopausal symptoms in this population remains underexplored. This study examined their temporal trajectory and clinical significance during adjuvant chemotherapy.

Method

This prospective study assessed breast cancer patients undergoing adjuvant chemotherapy at a tertiary hospital. Participants were classified by menopausal status and treated with AC-D (Adriamycin, Cyclophosphamide, and Docetaxel) or FAC (5-Fluorouracil, Adriamycin, and Cyclophosphamide) regimens. Menopausal symptoms were evaluated using the Menopausal Rating Scale (MRS) at four time points: before chemotherapy (T0), after the first (T1) and fourth (T2) cycles, and one month post-chemotherapy (T3). Symptom trajectories were analyzed using a linear mixed-effects model (LMM) and Generalized Estimating Equations (GEE).

Results

Menopausal symptoms significantly worsened in premenopausal women (AC-D: p < 0.001, FAC: p < 0.001), particularly from T2 onward. Psychological symptoms showed the greatest increase (AC-D: p < 0.001, FAC: p < 0.001), followed by significant worsening of urogenital symptoms (AC-D: p = 0.002, FAC: p = 0.004). Somatic symptoms showed a non-significant increasing trend (AC-D: p = 0.120, FAC: p = 0.101). At T3, 67.9% of AC-D and 59.4% of FAC patients experienced moderate-to-severe symptoms, with severe cases doubling in AC-D (from 16.1% at T0 to 37.5%) and tripling in FAC (6.8% at T0 to 18.9%).

Conclusion

Chemotherapy-induced menopausal symptoms progressively worsened, particularly psychological symptoms. By treatment completion, approximately two-thirds required clinical intervention, underscoring the need for early assessment and proactive management to improve patient outcomes.